PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Autism Consortium 2010 Symposium: New therapeutics focus, family resource guide announced

Researchers, clinicians and parents gather to discuss latest autism research

2010-11-02
(Press-News.org) Boston – November 1, 2010 – The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.

"As scientists are starting to connect genetics to brain function and behavior, we believe it is time to capitalize on these findings and focus our efforts on helping to fulfill the promise of translational medicine for people with autism and their families," said Peter Barrett, partner in the Life Sciences group at Atlas Venture and chair of the Autism Consortium's board of directors, who spoke at the Symposium. The annual meeting gave scientists, clinicians, parents and service providers an opportunity to gather to hear about the latest information on causes of autism, research into new methods for diagnosis, and advances in therapeutics for people with autism spectrum disorders.

As part of the new therapeutics initiative, the first session of the afternoon brought together speakers representing clinical trials for therapeutics in three autism-related disorders: Rett Syndrome, Tuberous Sclerosis and Fragile X. Capitalizing on this opportunity, Robert Ring, PhD, the Senior Director and Head of the newly established Autism Research Unit within Pfizer Global Research and Development spoke about how academia and the pharmaceutical industry can leverage collaboration in the pursuit of autism therapeutics.

"The future of therapeutic discovery and development for patients living with autism cannot be built without a strong foundation of collaborative partnership between industry and academia," said Dr. Ring. "Non-profit organizations like the Autism Consortium will be critical partners in bringing these collaborative partnerships together."

In addition to Pfizer, attendees included representatives from a number of pharmaceutical companies including: Biogen Idec, Bristol Myers Squibb, Hoffman-LaRoche, Merck, Novartis, Sanofi-Aventis, Seaside Therapeutics, and Shire.

New Resource Guide for Families Released

At the Symposium, the Autism Consortium also announced the release of a new guide: "Transitioning Teens with Autism Spectrum Disorders: Resources and Timeline Planning for Adult Living". The manual is designed to provide concise insight on the key considerations and timeline for the journey. It includes valuable information on healthcare, post secondary education, employment and training, living arrangements, guardianship, and a host of other topics that will help parents navigate as their teens age out of childhood support services.

"With promising scientific research underway and many resources available to families of younger children, there was a decided lack of clear information and guidance on the transition to adult living. This manual is intended to fill the gap so families can constructively create a safe and meaningful context for their young adult's life," said Deirdre Phillips, Autism Consortium Executive Director. "We know that care providers, educators, community and government agencies are most responsive when families are knowledgeable and proactive advocates, and we believe this manual will be a valuable tool for them."

Current Autism Issues Discussed

The Plenary morning session included talks on new and exciting uses of informatics in autism research: Alexa McCray, PhD, Associate Professor of Medicine at Harvard Medical School and Co-Director, Center for Biomedical Informatics discussed tools that are making the vast amounts of Autism Consortium phenotyping data searchable and more accessible to researchers. She also presented an Autism Phenotype Ontology that will help to aggregate data from over 25 phenotpying tests, which measure the cognitive, behavioral and biological features of autism. This ontology will allow researchers world-wide to share their data more easily and potentially ease the burden of participating families by defining overlaps between the phenotyping measures. Dennis Wall, PhD, Assistant Professor at the Center for Biomedical Informatics of Harvard Medical School discussed using datasets from genome wide scans to discover and validate new genes and pathways implicated in ASDs.

A second morning session focused on new research into early identification and diagnosis of autism. Christopher A. Walsh, MD, PhD, Investigator, Howard Hughes Medical Institute, the Bullard Professor of Neurology at Harvard Medical School and Chief, Division of Genetics at Children's Hospital Boston outlined the current state of screening and diagnostic methods and the importance of evolving research in this area. Charles Nelson III, PhD, Professor of Pediatrics and Neuroscience at Harvard Medical School, and the Richard David Scott Chair in Pediatric Developmental Medicine Research at Children's Hospital Boston discussed using sophisticated electrophysiological and neuroimaging tools for early identification of infants at risk for autism. Louis Kunkel, PhD, Director, Program in Genomics at Children's Hospital Boston, and Professor of Pediatrics and Genetics at Harvard Medical School previewed his research on using whole blood expression profiles as a diagnostic for autism.

Latest Autism Research Presented for Discussion

Throughout the day, 22 researchers presented posters on their ongoing research in autism, ranging from new advances in clinical care to data mining, RNA editing and genomic arrangements.

Autism Spectrum Disorders Clinical Trials Update

The first afternoon session, lead by Mriganka Sur, PhD, Newton Professor of Neuroscience, and Head of the Department of Brain and Cognitive Sciences at MIT, included updates on clinical trials in disorders related to autism, as well as a discussion on collaborations between academia and industry, led by Robert Ring, PhD, Senior Director and Head of the Autism Research Unit at Pfizer Global Research and Development.

Omar Khwaja, MD, PhD Assistant in Neurology and Director of the Rett Syndrome Program at Children's Hospital Boston, and Instructor in Neurology at Harvard Medical School presented an overview of a new clinical trial for Rett Syndrome underway at Children's Hospital Boston. Kira Dies, ScM, LGC, Program Manager of the Tuberous Sclerosis Program at Children's Hospital Boston, gave an update on two clinical trials underway for Tuberous Sclerosis. Paul Wang, MD, Vice President of Clinical Development at Seaside Therapeutics presented work on promising trials underway for Fragile X Syndrome.

Close-Up on Autism Genetics

The second afternoon session, lead by James Gusella, PhD, Bullard Professor of Neurogenetics at Harvard Medical School, and Director of Center for Human Genetic Research at Massachusetts General Hospital, took an in-depth look at several recent findings in the area of genetics related to ASDs. Michael Talkowski, PhD, Postdoctoral Fellow in the Gusella Laboratory at MGH presented his work on using novel sequencing methods to characterize balanced rearrangements to identify high impact genomic targets in autism and related neurodevelopmental disorders. Seema Jamal, MSc, LGC, CCGC, Instructor of Pediatrics at Boston University School of Medicine presented her work on understanding the genetics of Epilepsy Limited to Females with Mental Retardation syndrome and how that relates to Autism Spectrum Disorders.

### About the Autism Consortium

The Autism Consortium is a scientific and clinical collaboration that includes 14 institutions, supported by a non-profit that is dedicated to facilitating and catalyzing research and improving clinical care. The mission of the Autism Consortium is to catalyze rapid advances in understanding and diagnosis of autism by engaging, supporting, and fostering collaboration among a community of clinicians, researchers, donors and families in order to improve the treatment of children and families affected by autism and other neurological disorders. The Consortium brings together some of the best minds across the region from Beth Israel Deaconess Medical Center, Boston Medical Center, Boston University, Boston University School of Medicine, Broad Institute, Children's Hospital Boston, Harvard Medical School, Harvard University, Massachusetts Institute of Technology, McLean Hospital Massachusetts General Hospital, the Lurie Family Autism Center/LADDERS at MGH, , The Floating Hospital for Children at Tufts Medical Center, UMASS Medical School , UMASS Memorial Health Care.

To learn more about the Autism Consortium, please visit www.autismconsortium.org

END



ELSE PRESS RELEASES FROM THIS DATE:

Grasses have potential as alternate ethanol crop, Illinois study finds

Grasses have potential as alternate ethanol crop, Illinois study finds
2010-11-02
CHAMPAIGN, Ill. — Money may not grow on trees, but energy could grow in grass. Researchers at the University of Illinois have completed the first extensive geographic yield and economic analysis of potential bioenergy grass crops in the Midwestern United States. Demand for biofuels is increasing as Americans seek to expand renewable energy sources and mitigate the effects of fluctuating energy prices. Corn ethanol is the main biofuel on the market, but demand for ethanol competes with corn's availability as a food, and rising ethanol consumption could lead to higher food ...

Of 50,000 small molecules tested to fight cancer, 2 show promise

2010-11-02
BOSTON (3:00 p.m. ET, November 1, 2010) — A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death. "PITs cause cells to self-destruct by interfering with the signaling pathways that regulate cell survival. As compounds that promote cell death, PITs show promise in halting ...

Anger makes people want things more

2010-11-02
Anger is an interesting emotion for psychologists. On the one hand, it's negative, but then it also has some of the features of positive emotions. For a new study published in Psychological Science, a journal of the Association for Psychological Science, researchers find that associating an object with anger actually makes people want the object—a kind of motivation that's normally associated with positive emotions. People usually think of anger as a negative emotion. You're not supposed to get angry. But anger also has some positive features. For example, it activates ...

New way of removing excess nitrogen from the environment

2010-11-02
Excess nitrogen from agricultural and urban lands is contaminating groundwater, streams, lakes and estuaries, where it causes harmful algal blooms and contributes to fish kills. Cost-effective approaches to removing this nitrogen from croplands and urban stormwater runoff before it reaches sensitive water bodies have been elusive. But simple and inexpensive technologies are on the horizon. A recent scientific workshop on denitrification brought together ecologists, engineers and policy experts to find answers. Denitrification is a biological process carried out by ...

NYU Courant researchers develop algebraic model to monitor cellular change

2010-11-02
Researchers at New York University's Courant Institute of Mathematical Sciences have developed a novel algebraic model of DNA "hybridization," a process central to most biotechnology devices that monitor changes in cell's gene expression or characterize a cell's genome. Their work, which is described in the journal Physical Review E, provides an additional tool for understanding how biological systems function and could enhance methods and designs of technologies used in cancer and genetics research. Biology researchers seek to measure cell activity, but the task is a ...

Lead poisoning maps in R.I. reveal huge disparities, guide cleanup

2010-11-02
PROVIDENCE, R.I. [Brown University] — The rate at which lead poisoning has struck young Rhode Island children depends heavily on where they live, according to a Brown University-led geographic analysis of comprehensive health department data from across Rhode Island between 1993 and 2005. By mapping cases of lead poisoning, researchers have been able to help target cleanup resources to do the most good. During that 12-year period, some census blocks in the state had no cases of poisoning in the study group of 204,746 children, but in the hardest hit census blocks of Providence, ...

Imaging in depth: 3-dimensional microscopy featured in Cold Spring Harbor Protocols

2010-11-02
COLD SPRING HARBOR, N.Y. (Mon., Nov. 1, 2010) -- Imaging has rapidly become a defining tool of the current era in biological research. But finding the right method and optimizing it for data collection can be a daunting process, even for an established imaging laboratory. Cold Spring Harbor Protocols is one of the world's leading sources for detailed technical instruction for implementation of imaging methods (http://cshprotocols.cshlp.org/cgi/collection/imaging_microscopy_general), and the November issue (http://cshprotocols.cshlp.org/TOCs/toc11_10.dtl) features articles ...

Pitt study finds NSAIDs cause stem cells to self-destruct, preventing colon cancer

2010-11-02
PITTSBURGH, Nov. 1 – Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine. Their findings, reported in the early online version of this week's Proceedings of the National Academy of Sciences, could lead to new strategies to protect people at high risk for the disease. Doctors have long known that NSAIDs, such as aspirin, can lower the risk of colon cancer, but it's not been ...

Rutgers, Chilean astrophysicists discover new galaxy clusters revealed by cosmic 'shadows'

Rutgers, Chilean astrophysicists discover new galaxy clusters revealed by cosmic shadows
2010-11-02
NEW BRUNSWICK, N.J. – An international team of scientists led by Rutgers University astrophysicists have discovered 10 new massive galaxy clusters from a large, uniform survey of the southern sky. The survey was conducted using a breakthrough technique that detects "shadows" of galaxy clusters on the cosmic microwave background radiation, a relic of the "big bang" that gave birth to the universe. In a paper published in the Nov. 10 issue of Astrophysical Journal, the Rutgers scientists and collaborators at the Pontifical Catholic University of Chile (PUC) describe their ...

Microfluidics-imaging platform detects cancer growth signaling in minute biopsy samples

2010-11-02
Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity. Now, UCLA researchers from the Crump Institute for Molecular Imaging, the Institute for Molecular Medicine, the California NanoSystems Institute, the Jonsson Comprehensive Cancer Center and the department ...

LAST 30 PRESS RELEASES:

Long-sought structure of powerful anticancer natural product solved by integrated approach

World’s oldest lizard wins fossil fight

Simple secret to living a longer life

Same plant, different tactic: Habitat determines response to climate

Drinking plenty of water may actually be good for you

Men at high risk of cardiovascular disease face brain health decline 10 years earlier than women

Irregular sleep-wake cycle linked to heightened risk of major cardiovascular events

Depression can cause period pain, new study suggests

Wistar Institute scientists identify important factor in neural development

New imaging platform developed by Rice researchers revolutionizes 3D visualization of cellular structures

To catch financial rats, a better mousetrap

Mapping the world's climate danger zones

Emory heart team implants new blood-pumping device for first time in U.S.

Congenital heart defects caused by problems with placenta

Schlechter named Cancer Moonshot Scholar

Two-way water transfers can ensure reliability, save money for urban and agricultural users during drought in Western U.S., new study shows

New issue of advances in dental research explores the role of women in dental, clinical, and translational research

Team unlocks new insights on pulsar signals

Great apes visually track subject-object relationships like humans do

Recovery of testing for heart disease risk factors post-COVID remains patchy

Final data and undiscovered images from NASA’s NEOWISE

Nucleoporin93: A silent protector in vascular health

Can we avert the looming food crisis of climate change?

Alcohol use and antiobesity medication treatment

Study reveals cause of common cancer immunotherapy side effect

New era in amphibian biology

Harbor service, VAST Data provide boost for NCSA systems

New prognostic model enhances survival prediction in liver failure

China focuses on improving air quality via the coordinated control of fine particles and ozone

Machine learning reveals behaviors linked with early Alzheimer’s, points to new treatments

[Press-News.org] Autism Consortium 2010 Symposium: New therapeutics focus, family resource guide announced
Researchers, clinicians and parents gather to discuss latest autism research